Summary
Approval bodies such as the FDA, EMA and NICE will soon focus on patient preference evidence when approving new medical treatments. It is therefore inevitable that pharma HQs will begin generating such evidence and expecting affiliates to utilize such evidence in Market Access and Commercial work.
At this course you gain an understanding of what Patient Preferences is, which methods to generate and measure patient preferences and how they can be used in a Danish context when working with Payers, HCPs and patient organizations.
Key words
- Patient preferences
- Patient Advocacy
- Medical Affairs
- Market Access
- Stakeholder management
- Health data
- Evidence
- Medicine evaluation
- Danish Medicines Council
Hi! Do you need help choosing the right course?
We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com
Course leader(s) & Lecturers
- Arun MicheelsenCourse leaderChefkonsulent
DLI Market Intelligence ApS - Elisabeth Gammelgaard LudvigCourse leaderOwner
Sundhedsagenda - Agathe Le LayLecturerSenior Director and Global Head of Value Evidence
Lundbeck A/S - Leif Vestergaard PedersenLecturerDanske Patienters repræsentant
Medicinrådet - Karina Dahl SteffensenLecturerProfessor, Overlæge v. Onkologisk Afdeling og Leder af Center for Fælles Beslutningstagning
Sygehus Lillebælt - Rie Stjærnholm TrærupLecturerBrand Lead
Bristol-Myers Squibb - Søren Esben HansenLecturerSenior Advisor
DLI Market Intelligence ApS
IS THIS COURSE FOR YOU?
This course is essential for you if you work with Medical Affairs, Market Access, Public Affairs, Sales, Marketing or Patient Advocacy.
Others interested in learning about patient preferences are also welcome.
What you will learn
- What patient preferences are and how they can be generated quantitatively and qualitatively
- How international approval bodies work with patient preferences, including the expectations of the Danish Medicines Council for the role played by the preferences in the Council's work in the future
- The relationship between HQ and subsidiaries regarding patient preferences
- How healthcare professionals and patients’ associations work with patient preferences in everyday life, and how pharmaceutical companies can contribute to that work
What your company will get
- An employee who understands patient preferences and how these can be utilised in cross-functional work during the product lifecycle from development and pre-approval to launch and post-launch
- An employee with knowledge about how patient preferences are included in approval bodies’ decision-making processes
Calendar
DAY 1
- A HQ’s work with patient preferences and its’ expectations for affiliates
- The Danish Medicines Council view on patient preference data
- How do physicians work with patient preferences and decision tools in the daily clinic?
- Knowledge on patient preferences can improve the introduction of new treatment
- Discussion and conclusions
Registration
Registration deadline3. Nov 2021
Lersø Parkallé 101
2100 København Ø
Course information
Literature
Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.
Please familiarize yourself with the mandatory readings before starting the course.
The mandatory readings are also part of the examination syllabus.
Please download and read whitepaperet “The value of patient preference, DLIMI”. You can download it here.
Examination
There is no examination for this course.
Course leader(s)
DLI Market Intelligence ApS
Sundhedsagenda
Lecturers
DLI Market Intelligence ApS
Lundbeck A/S
Medicinrådet
Sygehus Lillebælt
Bristol-Myers Squibb
DLI Market Intelligence ApS
You may also be interested in these courses
Want to know more or need help?
Contact Client Manager Birger Flinthagen at +45 39 15 09 06
Send me a message